OBJECTIVES: Impaired cognitive function in HIV-infected patients has been suggested. Treatment with combination antiretroviral therapy (cART) restores CD4⁺ cell counts and suppresses viral replication, but immune activation and inflammation may persist. The aim of the study was to examine if cognitive function in HIV-infected patients was related to immune activation and inflammation. METHODS: Sixty-one HIV-infected patients and 31 healthy controls were included. All patients were on treatment with cART, had suppressed viral replication, and had a mean CD4⁺ cell count of 522 cells/μL. Cognitive function was assessed using a test battery of neurocognitive tests. Plasma concentrations of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and β-2-microglobulin were measured. Immune activation (CD8⁺HLR-DR⁺CD38⁺ cells) was determined using flow cytometry. Multiple linear regression analysis was performed to identify relationship between cognitive scores and markers of inflammation and immune activation. RESULTS: HIV-infected patients had intact cognitive function compared with healthy controls. Higher levels of TNF-α, β-2-microglobulin, and chronic activated CD8⁺ cells were found in HIV-infected patients (P = 0.0002, P < 0.0001, and P = 0.021, respectively). Weak negative correlations were found between chronic activated CD8⁺ cells (β-coefficient = -0.277, P = 0.044), IL-6 (β-coefficient = -0.280, P = 0.014), and memory and learning. CONCLUSIONS: HIV-infected patients on cART with undetectable viral load had an increased level of inflammation and immune activation. However, intact cognitive function was found, and only weak correlations were found between cognitive function and markers of inflammation and immune activation, indicating that peripheral inflammation and immune activation are not major drivers of cognitive decay in HIV-infected patients.
OBJECTIVES: Impaired cognitive function in HIV-infectedpatients has been suggested. Treatment with combination antiretroviral therapy (cART) restores CD4⁺ cell counts and suppresses viral replication, but immune activation and inflammation may persist. The aim of the study was to examine if cognitive function in HIV-infectedpatients was related to immune activation and inflammation. METHODS: Sixty-one HIV-infectedpatients and 31 healthy controls were included. All patients were on treatment with cART, had suppressed viral replication, and had a mean CD4⁺ cell count of 522 cells/μL. Cognitive function was assessed using a test battery of neurocognitive tests. Plasma concentrations of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and β-2-microglobulin were measured. Immune activation (CD8⁺HLR-DR⁺CD38⁺ cells) was determined using flow cytometry. Multiple linear regression analysis was performed to identify relationship between cognitive scores and markers of inflammation and immune activation. RESULTS:HIV-infectedpatients had intact cognitive function compared with healthy controls. Higher levels of TNF-α, β-2-microglobulin, and chronic activated CD8⁺ cells were found in HIV-infectedpatients (P = 0.0002, P < 0.0001, and P = 0.021, respectively). Weak negative correlations were found between chronic activated CD8⁺ cells (β-coefficient = -0.277, P = 0.044), IL-6 (β-coefficient = -0.280, P = 0.014), and memory and learning. CONCLUSIONS:HIV-infectedpatients on cART with undetectable viral load had an increased level of inflammation and immune activation. However, intact cognitive function was found, and only weak correlations were found between cognitive function and markers of inflammation and immune activation, indicating that peripheral inflammation and immune activation are not major drivers of cognitive decay in HIV-infectedpatients.
Authors: Marius Trøseid; Ingjerd W Manner; Karin K Pedersen; Judith M Haissman; Dag Kvale; Susanne D Nielsen Journal: AIDS Res Hum Retroviruses Date: 2014-03-25 Impact factor: 2.205
Authors: Javed Butler; Stephen J Greene; Svati H Shah; Sanjiv J Shah; Kevin J Anstrom; Raymond J Kim; Andreas P Kalogeropoulos; Eric J Velazquez; Adrian F Hernandez; Patrice Desvigne-Nickens; Rebecca Scherzer; Priscilla Y Hsue; Eugene Braunwald Journal: J Card Fail Date: 2019-11-02 Impact factor: 5.712
Authors: Andrew J Levine; Steve Horvath; Eric N Miller; Elyse J Singer; Paul Shapshak; Gayle C Baldwin; Otoniel Martínez-Maza; Mallory D Witt; Peter Langfelder Journal: J Neuroimmunol Date: 2013-09-26 Impact factor: 3.478
Authors: S K Nissen; J F Højen; K L D Andersen; E Kofod-Olsen; R K Berg; S R Paludan; L Østergaard; M R Jakobsen; M Tolstrup; T H Mogensen Journal: Clin Exp Immunol Date: 2014-07 Impact factor: 4.330
Authors: Javed Butler; Andreas P Kalogeropoulos; Kevin J Anstrom; Priscilla Y Hsue; Raymond J Kim; Rebecca Scherzer; Sanjiv J Shah; Svati H Shah; Eric J Velazquez; Adrian F Hernandez; Patrice Desvigne-Nickens; Eugene Braunwald Journal: J Card Fail Date: 2018-03-02 Impact factor: 5.712
Authors: Lori E Arbeitman; Robert C O'Brien; Gabriel Somarriba; Sarah E Messiah; Daniela Neri; Gwendolyn B Scott; Tracie L Miller Journal: J Pediatr Gastroenterol Nutr Date: 2014-10 Impact factor: 2.839